Why the study?
Does aspirin use cause haemolysis in G6PD deficient patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Does aspirin use cause haemolysis in G6PD deficient patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Aspirin appears safe in G6PD deficient patients with ACS, with no reported cases of haemolysis in the literature.
May support aspirin in G6PD-deficient ACS patients post-stenting; leaves open need for prospective trials before practice change.
The use of aspirin, as part of a dual antiplatelet therapy regimen, is an established standard following coronary stenting in patients suffering from acute coronary syndrome (ACS). However, in glucose-6-phosphate dehydrogenase (G6PD) deficient patients, precaution is always taken with aspirin use, due to the risk of haemolysis. We reviewed all previous cases of G6PD deficient patients with ACS, in addition to a review of the available literature, to better understand the safety of aspirin use in this population. To date, there are no reported cases of haemolysis following aspirin use in this patient group and no guideline is established to date.
No takes yet. Share an insight, caveat, or question.
Feghaly et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: